Brokerages Anticipate Syneos Health Inc (NASDAQ:SYNH) to Announce $0.83 EPS

Brokerages expect Syneos Health Inc (NASDAQ:SYNH) to announce $0.83 earnings per share for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Syneos Health’s earnings, with the highest EPS estimate coming in at $0.84 and the lowest estimate coming in at $0.82. Syneos Health posted earnings of $0.75 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 10.7%. The business is scheduled to issue its next earnings results before the market opens on Thursday, October 31st.

According to Zacks, analysts expect that Syneos Health will report full-year earnings of $3.17 per share for the current fiscal year, with EPS estimates ranging from $3.15 to $3.18. For the next fiscal year, analysts forecast that the company will report earnings of $3.64 per share, with EPS estimates ranging from $3.54 to $3.71. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Syneos Health.

Syneos Health (NASDAQ:SYNH) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.02. Syneos Health had a net margin of 0.36% and a return on equity of 9.82%. The firm had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. During the same period in the previous year, the company earned $0.62 EPS. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year.

A number of equities research analysts recently weighed in on the company. SunTrust Banks raised their price objective on Syneos Health to $68.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Jefferies Financial Group boosted their target price on shares of Syneos Health from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Zacks Investment Research downgraded shares of Syneos Health from a “buy” rating to a “hold” rating and set a $55.00 target price for the company. in a report on Tuesday, September 10th. ValuEngine lowered shares of Syneos Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 9th. Finally, UBS Group raised their price target on shares of Syneos Health from $53.50 to $57.00 and gave the company a “neutral” rating in a report on Thursday, August 29th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $59.50.

Several institutional investors and hedge funds have recently modified their holdings of the company. Boston Advisors LLC acquired a new stake in shares of Syneos Health in the 2nd quarter worth $1,257,000. BB&T Corp increased its position in Syneos Health by 8.1% during the 2nd quarter. BB&T Corp now owns 8,749 shares of the company’s stock valued at $448,000 after buying an additional 656 shares in the last quarter. Tiverton Asset Management LLC acquired a new position in Syneos Health during the 2nd quarter valued at about $279,000. Holocene Advisors LP increased its position in Syneos Health by 19.9% during the 2nd quarter. Holocene Advisors LP now owns 131,140 shares of the company’s stock valued at $6,700,000 after buying an additional 21,746 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in Syneos Health by 18.8% in the second quarter. Parametric Portfolio Associates LLC now owns 301,841 shares of the company’s stock valued at $15,421,000 after buying an additional 47,822 shares during the last quarter.

Syneos Health stock traded down $0.54 during midday trading on Tuesday, reaching $53.23. The stock had a trading volume of 327,700 shares, compared to its average volume of 351,344. The company has a quick ratio of 0.89, a current ratio of 0.89 and a debt-to-equity ratio of 0.99. The firm has a market cap of $5.56 billion, a price-to-earnings ratio of 20.32, a price-to-earnings-growth ratio of 1.88 and a beta of 1.51. Syneos Health has a 52-week low of $36.26 and a 52-week high of $56.34. The company has a fifty day moving average of $53.84 and a 200 day moving average of $49.40.

About Syneos Health

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Recommended Story: How to calculate the intrinsic value of a stock

Get a free copy of the Zacks research report on Syneos Health (SYNH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.